Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-centre Study of BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

NCT03976973 is registered in ClinicalTrials.gov with Mucpharm Pty Ltd as lead sponsor.

NCT NCT03976973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03976973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-centre Study of BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
Lead sponsor
Mucpharm Pty Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2022
Completion date
February 29, 2024
Enrollment
62 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mucinous adenocarcinoma, mucinous tumor, peritoneal cancer, pseudomyxoma peritonei